The team’s approach rests on a protein side chain-based network method, a technique in which each amino acid residue is represented as a node, and edges are drawn between residues whose side chains come into close non-covalent contact. Such contacts include the hydrogen bonds, hydrophobic interactions, and electrostatic attractions that hold proteins together without forming chemical bonds. Rather than analyzing a single static structure, the researchers averaged their network construction over many snapshots drawn from molecular dynamics simulations produced by D. E. Shaw Research, an unusually long and detailed set of simulations that capture the complex in motion at atomic resolution. Averaging across these frames filters out fleeting, transient contacts and reveals the persistent connectivity patterns that define the complex’s functional architecture.

Once the network is built, the analysis proceeds at multiple hierarchical levels. At the most local scale, the researchers examined cliques—fully connected subgroups of residues in which every member interacts with every other member. Cliques at the viral–human interface act as tightly knit hubs of interaction, and their abundance and composition reveal how densely the two proteins interlock. At the global scale, the team analyzed clusters of connected residues and performed percolation analysis, a concept borrowed from statistical physics that asks how a network holds together as connections are progressively removed. In a percolation framework, the strongest substructures are identified by stripping away weaker links and observing which clusters survive.

The central finding of the study is unambiguous: the SARS-CoV-2 spike protein forms a more dominant and robust connection with the human ACE2 receptor than SARS-CoV-1 does. At the global level, this superiority shows up clearly in the percolation results. When the researchers restricted the networks to only the strongest interfacial bonds, the interface cluster of the SARS-CoV-2–ACE2 complex persisted, remaining a single connected unit, whereas the corresponding cluster in the SARS-CoV-1–ACE2 complex fragmented. In other words, the stronger non-covalent interactions between the newer virus and its receptor form a self-reinforcing web that cannot be dismantled by discarding weak contacts—a hallmark of structural robustness.

The atomic-scale analysis tells a complementary story. In the SARS-CoV-2 complex, network cliques at the interface form in a manner that reflects denser and better-organized inter-protein communication. Cliques are demanding structures: because every residue in a clique must contact every other, their emergence signals a level of mutual reinforcement that looser collections of contacts lack. The fact that these clique structures at the SARS-CoV-2 interface consistently encode stronger connectivity provides a mechanistic, residue-level explanation for the virus’s enhanced receptor engagement, one that emerges naturally from the geometry of interactions rather than from any single pinned atom or bond.

Beyond confirming what virologists had suspected from binding-affinity measurements, the network framework delivers something more practical: an objective method to map how atomic-level non-covalent interactions give rise to global connectivity between any two amino acids in the complex. Bridging these scales has long been a challenge in molecular biophysics. A single hydrogen bond at an interface may seem inconsequential in isolation, yet through the network it can contribute to pathways of communication that span the entire protein assembly. The side chain-network approach makes this propagation explicit, allowing researchers to trace exactly which local interactions feed into which large-scale structural couplings, and to rank residues by their contribution to overall interface integrity.

Using this ranking ability, the team pinpointed key functional residues in SARS-CoV-2 that play important roles in establishing the higher connectivity with ACE2. These residues, identified through their network centrality and their participation in robust interfacial clusters and cliques, constitute the structural backbone of the viral grip on human cells. The authors also examined specific individual snapshots from the molecular dynamics trajectories rather than only time-averaged networks, and this analysis highlighted prominent variations in network topology across different conformations. The spike–ACE2 complex does not sit in a single rigid state; it explores a diverse conformational landscape, and the connectivity architecture shifts meaningfully from one moment to another. Capturing these fluctuations matters because a receptor-binding interface is a dynamic entity, and transient configurations may expose vulnerabilities or reveal alternative interaction modes.

Perhaps the most striking connection to real-world virology emerges when the network map is overlaid with the evolutionary record of the pandemic. The researchers found that most mutations occurring in the SARS-CoV-2 spike protein in variants of concern and variants of interest—including the currently active JN.1 variant and its subvariants—have been observed at the interface with the ACE2 receptor. This is precisely the region that the network analysis identifies as the seat of the virus’s enhanced connectivity. The convergence is telling: as the virus evolves to evade immunity generated by prior infection or vaccination, natural selection keeps returning to the same interfacial neighborhood that network science flags as functionally dominant. Mutations there can simultaneously alter antibody recognition and tune receptor binding, which explains why this region is both the engine of immune escape and the object of intense surveillance by public health laboratories worldwide.

This convergence between evolutionary observation and network topology gives the study practical significance for therapeutic design. If a defined set of residues sustains the robust connectivity between the viral spike and ACE2, then molecules that mimic the relevant receptor surface could, in principle, compete with ACE2 for spike binding and neutralize the virus. The authors note that their analyses highlight the importance of interface interactions and provide a rationale for designing receptor-like peptides and proteins to combat immunity-escaping variants. Because such decoys target the physical grip on ACE2 rather than the antibody-recognized epitopes that mutate most rapidly under immune pressure, they may retain effectiveness even as the virus drifts genetically—a property that conventional antibody drugs increasingly struggle to maintain against JN.1-descended lineages.

More broadly, the work demonstrates the value of complex-systems thinking in molecular biology. A virus–receptor complex is not merely a collection of atoms or a static ribbon diagram; it is a network whose resilience, communication pathways, and failure points determine biological function. By providing an objective, quantitative bridge from atomic non-covalent interactions to global connectivity between any two amino acids, the framework developed by Subramanyan and colleagues can in principle be applied to any protein complex, well beyond coronaviruses. For SARS-CoV-2 specifically, it delivers a durable conceptual map of why this virus binds human cells so effectively, why evolution keeps redrawing the same interfacial territory, and where next-generation antiviral designs might most productively aim as the virus continues to diversify.

Subject of Research: Network analysis of the SARS-CoV-2 spike–human ACE2 receptor complex connectivity

Article Title: From atomic to global connectivity in the structure of the SARS-CoV2-human ACE2 receptor complex

Article References: Subramanyan, V., Anto, A., Bhattacharyya, M., Vishveshwara, S., & Vishveshwara, S. (2026). From atomic to global connectivity in the structure of the SARS-CoV2-human ACE2 receptor complex. PLOS Complex Systems, 3(4), e0000096. https://doi.org/10.1371/journal.pcsy.0000096

Image Credits: AI Generated

DOI: 10.1371/journal.pcsy.0000096

Keywords: SARS-CoV-2, ACE2 receptor, spike protein, SARS-CoV-1, molecular dynamics, protein structure networks, percolation analysis, network cliques, variants of concern, JN.1 variant, immune escape, peptide design

The biological logic behind the combination is what sets it apart from many single-cell approaches. Solid tumors are not uniform targets; they are heterogeneous collections of malignant cells that deploy overlapping but distinct strategies to evade immune attack. Natural killer cells belong to the innate immune system and can recognize and destroy stressed or abnormal cells without needing to identify a specific tumor antigen, making them valuable against cancer cells that have downregulated the surface molecules T cells typically rely on. T lymphocytes, by contrast, mediate adaptive immunity: when primed against tumor antigens, they can mount targeted, antigen-specific killing and generate immunological memory. By infusing both cell types together, the investigators aimed to attack the tumor through complementary mechanisms, reducing the likelihood that an immune-escape variant could slip through unscathed.

The trial design reflected its early-phase purpose. This was a single-arm study, meaning there was no placebo or control group, and all nine enrolled patients received the active therapy. Each participant had a recurrent or progressive solid tumor and had already undergone between one and three prior lines of systemic treatment, placing them squarely in the population where standard options have been exhausted. SDH-Combi was manufactured from each patient’s own cells—an autologous approach that avoids the rejection risks associated with donor material—and was administered as an infusion once every two weeks, for up to eight infusions in total. The primary endpoint was safety and tolerability, while secondary endpoints included objective response rate, disease control rate, progression-free survival, and overall survival, with tumor measurements assessed according to the widely used RECIST v1.1 criteria.

On the safety front, the results were strikingly clean for a cell therapy. Among the nine treated patients, no grade 3 or higher treatment-related adverse event occurred, a finding the investigators report with a 95 percent confidence interval of 0.0 to 33.6 percent. No patient discontinued treatment because of toxicity, no cases of cytokine release syndrome were observed, and there were no anaphylactic reactions or treatment-related serious adverse events. Cytokine release syndrome—a potentially dangerous inflammatory cascade that has complicated other cellular immunotherapies, most famously CAR T cell treatments—was a particular concern the trial was designed to monitor, and its complete absence is a notable point in the therapy’s favor.

Tolerability metrics reinforced the safety picture. Six of the nine patients, or 66.7 percent, completed all eight planned infusions, and 64 of the 72 planned infusions across the study—88.9 percent—were actually administered, indicating that the treatment schedule was practical for most participants. The single serious adverse event in the trial was a grade 4 anemia in one patient, whose hemoglobin fell to a nadir of 4.5 grams per deciliter, but the investigators judged this event unlikely to be related to the study therapy. All other adverse events were grades 1 or 2, the mildest categories on the standard CTCAE v5.0 grading scale used to classify treatment-emergent events.

The preliminary efficacy signals, while modest, were not negligible. In the full analysis set of nine patients, the disease control rate—encompassing complete responses, partial responses, and stable disease—reached 66.7 percent, suggesting that for a majority of these heavily pretreated patients, the therapy was associated with at least a halt in tumor progression. The objective response rate, which counts only measurable tumor shrinkage, was 11.1 percent, corresponding to a single patient among the nine. Median overall survival had not been reached at the time of the safety assessment, though five of the nine patients had died by the follow-up date of 14 January 2026. The authors are appropriately measured about these numbers, noting that formal statistical inference is limited by the small, single-arm sample size and the absence of a comparator group.

One of the more intriguing aspects of the study is its attention to quality of life, an exploratory endpoint measured with the validated EORTC QLQ-C30 questionnaire. Patients reported improvements that crossed the threshold for a minimal clinically important difference—defined as a change of at least 10 points—in five of the six functional domains assessed: global health status and quality of life, physical functioning, role functioning, emotional functioning, and social functioning. All nine symptom domains also showed changes meeting or approaching that threshold, with constipation showing a marginal improvement of 11.1 points, while cognitive functioning did not reach the clinically important threshold. For a population of patients with advanced, recurrent cancer, subjective improvements in daily functioning and well-being carry real weight, even in an uncontrolled setting where placebo effects and natural fluctuation cannot be excluded.

The trial was conducted under ethical approval from the Institutional Review Board of the Ministry of Health of Mongolia, with clinical sites including hospitals in Ulaanbaatar, and was funded by Seoul Songdo Hospital in South Korea, where the cell processing facility manufactured the autologous products. The collaboration highlights how cellular immunotherapy research is expanding geographically, and the authors acknowledge the substantial manufacturing effort required to produce patient-specific cell products on a clinical schedule. Autologous therapies of this kind demand that a patient’s own immune cells be collected, processed, expanded, and quality-controlled before being reinfused—a logistical and technical undertaking that shapes which patients can be treated and how quickly.

The authors conclude that SDH-Combi was feasible and well tolerated, with preliminary signals of disease stabilization and quality of life improvement in previously treated patients, findings they say support further clinical evaluation of this biologically rational combination cellular immunotherapy. That framing is the appropriate one for a phase 1 study: the trial was never designed to prove efficacy, only to establish that the approach can be delivered safely and consistently. What it has demonstrated is that combining autologous natural killer cells with tumor-primed T lymphocytes can be done without the severe toxicities that have shadowed other cell therapies, and that the treatment can be administered on a demanding every-two-week schedule with most patients completing the full course.

The road ahead will require larger, controlled trials to determine whether the disease control signals translate into meaningful extensions of survival, and which tumor types benefit most. The field of combination cellular immunotherapy is betting on a simple premise: that cancers are too adaptable to be defeated by any single immune cell type, and that deploying innate and adaptive immunity together closes the escape routes tumors rely on. With no grade 3 or higher treatment-related events, nearly 90 percent of planned infusions delivered, and a majority of patients experiencing disease control, this first-in-human evaluation gives that premise its earliest real-world test—and a reason for the field to keep watching.

Subject of Research: Phase 1 trial of autologous NK cell and T lymphocyte combination immunotherapy for recurrent solid tumors

Article Title: Phase 1 clinical trial evaluating the safety and preliminary efficacy of autologous NK cells combined with T lymphocytes in patients with recurrent solid tumors

Article References: Kim, K.-J., Lee, N., Che, D. N., Lee, H.-J., Lee, H. N., Tungalag, S., Batsukh, K., Nyamdavaa, T., Sohn, S.-K., & Lee, J. K. (2026). Phase 1 clinical trial evaluating the safety and preliminary efficacy of autologous NK cells combined with T lymphocytes in patients with recurrent solid tumors. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04532-7

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04532-7

Keywords: NK cells, T lymphocytes, cellular immunotherapy, solid tumors, phase 1 trial, autologous therapy, cancer immunotherapy, RECIST, quality of life, cytokine release syndrome, disease control, immune escape

The review begins by cataloguing the mechanical abnormalities that define the solid tumor microenvironment. Desmoplastic tumors, such as pancreatic ductal adenocarcinoma, deposit dense stromal matrix rich in collagen, crosslinked in part by enzymes like lysyl oxidase, producing tissue that can be far stiffer than healthy surrounding tissue. Growing cell masses generate solid stress that compresses blood and lymphatic vessels, raising interstitial fluid pressure and distorting fluid flow. Cancer-associated fibroblasts amplify this stiffness by contracting the matrix and depositing new extracellular material. These physical cues are not passive background conditions; cells sense them through integrin-based adhesions, mechanosensitive ion channels, and cytoskeletal networks, converting mechanical information into biochemical signals that reach all the way into the nucleus and alter gene expression.

The canonical mechanotransduction pathways described in the review provide plausible routes by which physical forces could reach the RNA modification machinery. Integrin-focal adhesion kinase signaling couples matrix rigidity to downstream cascades including PI3K-AKT, MAPK, and Rho-associated kinase pathways. The transcriptional coactivators YAP and TAZ, which respond to substrate stiffness and cytoskeletal tension, shuttle into the nucleus under mechanical loading and reprogram transcription. The stretch-activated ion channel PIEZO1 converts membrane tension into calcium influx, triggering downstream signaling. Cytoskeletal remodeling and nuclear deformation, mediated in part by LINC complexes that physically connect the cytoskeleton to the nuclear interior, can even alter chromatin organization directly. Each of these conduits, the authors argue, represents a potential input channel to the enzymes that write, erase, and read chemical marks on RNA.

Those enzymes are the heart of the epitranscriptome. N6-methyladenosine, or m6A, is the most abundant internal modification of messenger RNA and is installed by writer complexes containing METTL3, METTL14, and WTAP, removed by erasers such as FTO and ALKBH5, and interpreted by readers including YTHDF proteins and IGF2BP family members. Other modifications, including 5-methylcytosine, 7-methylguanosine, and pseudouridine, together with adenosine-to-inosine RNA editing, further diversify the informational content of the transcriptome. The review emphasizes that the activity, localization, and expression of these writers, erasers, and readers could plausibly be modulated by mechanical signaling. For example, YAP/TAZ-driven transcriptional programs could alter the expression levels of modification enzymes, while calcium influx through PIEZO1 could regulate enzymatic activity through calcium-dependent signaling, and nuclear deformation could influence where modification enzymes reside within the cell.

The most striking aspect of the review is its intellectual honesty about the state of the evidence. The authors applied a tiered classification to the studies they surveyed and found that only two investigations meet the strictest Tier-1 definition of mechanosensitive epitranscriptomics in cancer-relevant systems. The first is a study in pancreatic ductal adenocarcinoma showing that substrate stiffness influences the METTL14 and IGF2BP3 axis in a YAP1-dependent manner, linking matrix rigidity to m6A deposition and downstream oncogenic outputs. The second demonstrates that mechanical stiffness regulates the m6A eraser FTO in macrophages, thereby controlling Socs1 expression and shaping macrophage polarization, a process central to tumor immune dynamics. Most other reported connections between mechanics and RNA modification, the authors caution, remain Tier-3 hypotheses or associations potentially confounded by parallel changes in oxygen tension, inflammation, or metabolism that accompany altered mechanical environments.

Distinguishing direct mechanoregulation from these secondary effects is a central challenge the review confronts head-on. A stiff, hypoperfused tumor region is simultaneously stiff, hypoxic, nutrient-deprived, and inflamed. Hypoxia-inducible factors can independently regulate RNA modification enzymes, and inflammatory cytokines such as transforming growth factor beta do the same. To untangle this web, the authors propose testable experimental models: decoupling stiffness from hypoxia using engineered matrices, applying controlled mechanical stretch to cells in isolation, and using temporally precise perturbations to determine whether mechanical inputs causally drive changes in RNA modification rather than merely correlating with them. Such designs, they argue, are essential before the field can claim that mechanics acts directly on the epitranscriptomic machinery rather than through intermediary stress responses.

The tumor-immune interface is where the stakes of this framework become highest. Mechanical stress and RNA modifications jointly influence nearly every process that determines whether a tumor is recognized and destroyed by the immune system. Antigen presentation depends on the translation and processing of major histocompatibility complex components, processes that m6A and other modifications can tune. Interferon signaling, which alert neighboring cells to the presence of tumor antigens, is sensitive to RNA editing levels, since adenosine-to-inosine editing can alter how double-stranded RNA is perceived by innate immune sensors. Checkpoint molecules such as PD-L1 are themselves subject to RNA modification control. The review details how these regulatory layers could affect T-cell and natural killer cell function, the polarization of myeloid cells toward immunosuppressive fates, and the physical exclusion of immune cells from tumor nests, where stromal stiffness forms a mechanical barrier to immune infiltration.

On the translational side, the review outlines strategies for converting this framework into clinical tools. Magnetic resonance elastography already allows noninvasive mapping of tissue stiffness in patients, and combining such mechanical imaging with single-cell epitranscriptomic profiling, using methods like single-cell RNA sequencing, methylated RNA immunoprecipitation sequencing, and deamination-based modification mapping, could reveal how mechanical niches within tumors correspond to distinct RNA modification states. The authors envision composite biomarkers that integrate tumor mechanics, epitranscriptomic signatures, and predicted immunotherapy response, potentially identifying patients likely to benefit from immune checkpoint blockade. They also suggest that enzymes such as FTO, METTL14, or METTL3 could themselves become therapeutic targets, either alone or in combination with mechanical normalization strategies such as drugs that reduce matrix stiffness or stromal pressure, thereby softening the tumor microenvironment while simultaneously reprogramming RNA regulation.

What makes this review compelling is its refusal to overstate a young field. By explicitly ranking the evidence and naming the two Tier-1 studies, the authors provide a benchmark against which future work can be measured, and they openly acknowledge that much of the mechanosensitive epitranscriptomic landscape in cancer remains hypothetical. Yet the framework they assemble is rich with testable predictions: that specific mechanotransduction channels converge on specific modification enzymes, that these enzymes modify specific transcript subsets governing immune recognition, and that disrupting these circuits could restore immune visibility to mechanically armored tumors. As sequencing technologies for RNA modifications grow faster and more precise, and as engineered matrices allow cleaner mechanical experiments, the coming years should reveal whether the convergence of tumor mechanics and RNA chemistry is a genuine biological axis or a seductive correlation. Either way, the review establishes a clear roadmap for finding out, and in doing so adds a provocative new dimension to the ongoing effort to understand why some tumors so successfully hide from the immune system.

Subject of Research: How tumor mechanics regulate RNA modifications and immune escape in cancer

Article Title: Mechanosensitive epitranscriptomics in cancer: linking tumor mechanics, RNA modification, and immune escape

Article References: Jiang, M., Zhang, K., Li, M., Yao, J., Shi, R., Sun, C., Rodríguez, R. A., Lin, Z., Meng, J., Wang, Z., Wu, S., Luo, M., Zhang, W., Wei, R., Bai, Y., Lai, G., Zhang, C., Bo, Z., & Wang, T. (2026). Mechanosensitive epitranscriptomics in cancer: linking tumor mechanics, RNA modification, and immune escape. Molecular Cancer. https://doi.org/10.1186/s12943-026-02784-6

Image Credits: AI Generated

DOI: 10.1186/s12943-026-02784-6

Keywords: mechanosensitive epitranscriptomics, RNA modifications, m6A, mechanotransduction, tumor microenvironment, immune escape, cancer immunotherapy, YAP/TAZ, METTL14, FTO, tumor stiffness, Molecular Cancer